Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. NASH Cirrhosis Full Year 2024 Financial Highlights As of December 31, 2024, the Company had $15.1 million of unrestricte ...